{"id": "VqskH6cAAAAJ", "citedby": 37350, "citedby5y": 22132, "hindex": 95, "hindex5y": 67, "i10index": 270, "i10index5y": 179, "coauthors": [], "name": "Thomas F Gajewski", "affiliation": "Professor, University of Chicago", "interests": ["cancer", "immunology"], "cites_per_year": {"1991": 155, "1992": 178, "1993": 267, "1994": 290, "1995": 353, "1996": 346, "1997": 414, "1998": 502, "1999": 511, "2000": 503, "2001": 514, "2002": 473, "2003": 529, "2004": 560, "2005": 527, "2006": 674, "2007": 765, "2008": 729, "2009": 759, "2010": 823, "2011": 980, "2012": 1041, "2013": 1360, "2014": 1524, "2015": 2097, "2016": 3024, "2017": 3803, "2018": 4784, "2019": 5556, "2020": 2730}, "publications": [{"bib": {"title": "Innate and adaptive immune cells in the tumor microenvironment", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:D_sINldO8mEC", "citedby": "1735"}, {"bib": {"title": "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_axFR9aDTf0C", "citedby": "1336"}, {"bib": {"title": "Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.", "year": "1988"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hC7cP41nSMkC", "citedby": "1064"}, {"bib": {"title": "Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:u-x6o8ySG0sC", "citedby": "1058"}, {"bib": {"title": "Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:DyXnQzXoVgIC", "citedby": "1045"}, {"bib": {"title": "Helper T cell differentiation is controlled by the cell cycle", "year": "1998"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:PR6Y55bgFSsC", "citedby": "910"}, {"bib": {"title": "PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:86PQX7AUzd4C", "citedby": "737"}, {"bib": {"title": "Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:EUQCXRtRnyEC", "citedby": "669"}, {"bib": {"title": "STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:raTqNPD5sRQC", "citedby": "652"}, {"bib": {"title": "Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ns9cj8rnVeAC", "citedby": "615"}, {"bib": {"title": "STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:5icHVeHT4IsC", "citedby": "614"}, {"bib": {"title": "The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:7BrZ7Jt4UNcC", "citedby": "608"}, {"bib": {"title": "Cancer classification using the Immunoscore: a worldwide task force", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:jE2MZjpN3IcC", "citedby": "575"}, {"bib": {"title": "Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ULOm3_A8WrAC", "citedby": "547"}, {"bib": {"title": "Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:g5Ck-dwhA_QC", "citedby": "504"}, {"bib": {"title": "Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:8d8msizDQcsC", "citedby": "491"}, {"bib": {"title": "Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:IRz6iEL74y4C", "citedby": "452"}, {"bib": {"title": "Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4fKUyHm3Qg0C", "citedby": "450"}, {"bib": {"title": "Blocked Ras activation in anergic CD4+ T cells", "year": "1996"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:43bX7VzcjpAC", "citedby": "437"}, {"bib": {"title": "A peptide encoded by human gene MAGE\u20103 and presented by HLA\u2010A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE\u20103", "year": "1994"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:6ZxmRoH8BuwC", "citedby": "436"}, {"bib": {"title": "Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.", "year": "1991"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HtEfBTGE9r8C", "citedby": "428"}, {"bib": {"title": "Differential regulation of murine T lymphocyte subsets", "year": "1993"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:RoXSNcbkSzsC", "citedby": "427"}, {"bib": {"title": "Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant \u2026", "year": "1989"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:fEOibwPWpKIC", "citedby": "423"}, {"bib": {"title": "Immune resistance orchestrated by the tumor microenvironment", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Ehil0879vHcC", "citedby": "420"}, {"bib": {"title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Y5dfb0dijaUC", "citedby": "412"}, {"bib": {"title": "Apoptosis meets signal transduction: elimination of a BAD influence", "year": "1996"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:CYCckWUYoCcC", "citedby": "406"}, {"bib": {"title": "Tumor and microenvironment evolution during immunotherapy with nivolumab", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:oNZyr7d5Mn4C", "citedby": "392"}, {"bib": {"title": "The immune score as a new possible approach for the classification of cancer", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:UebtZRa9Y70C", "citedby": "386"}, {"bib": {"title": "Blockade of PD\u2010L1 (B7\u2010H1) augments human tumor\u2010specific T cell responses in vitro", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:wbdj-CoPYUoC", "citedby": "348"}, {"bib": {"title": "Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:wMgC3FpKEyYC", "citedby": "323"}, {"bib": {"title": "PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ipzZ9siozwsC", "citedby": "320"}, {"bib": {"title": "Phase I/II trial of tremelimumab in patients with metastatic melanoma", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:XvxMoLDsR5gC", "citedby": "315"}, {"bib": {"title": "Mechanism of tumor rejection with doublets of CTLA-4", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:nrtMV_XWKgEC", "citedby": "302"}, {"bib": {"title": "Immune suppression in the tumor microenvironment", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:PyEswDtIyv0C", "citedby": "293"}, {"bib": {"title": "Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:zLWjf1WUPmwC", "citedby": "269"}, {"bib": {"title": "CCI\u2010779 in metastatic melanoma: a phase II trial of the California Cancer Consortium", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:5awf1xo2G04C", "citedby": "266"}, {"bib": {"title": "Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kzcSZmkxUKAC", "citedby": "260"}, {"bib": {"title": "Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly \u2026", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:9yKSN-GCB0IC", "citedby": "256"}, {"bib": {"title": "Increasing tumor antigen expression overcomes \u201cignorance\u201d to solid tumors via crosspresentation by bone marrow-derived stromal cells", "year": "2002"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:uWQEDVKXjbEC", "citedby": "256"}, {"bib": {"title": "T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-\u03b1", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HoB7MX3m0LUC", "citedby": "254"}, {"bib": {"title": "Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:2ywjKiB__4kC", "citedby": "252"}, {"bib": {"title": "Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones.", "year": "1990"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:UuEBAcK4md4C", "citedby": "245"}, {"bib": {"title": "Innate immune recognition of cancer", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ZHo1McVdvXMC", "citedby": "244"}, {"bib": {"title": "Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:6yz0xqPARnAC", "citedby": "240"}, {"bib": {"title": "Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:3bvyWxjaHKcC", "citedby": "233"}, {"bib": {"title": "Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:a0OBvERweLwC", "citedby": "232"}, {"bib": {"title": "Glucose availability regulates IFN-\u03b3 production and p70S6 kinase activation in CD8+ effector T cells", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:3s1wT3WcHBgC", "citedby": "226"}, {"bib": {"title": "Costimulatory and coinhibitory receptors in anti\u2010tumor immunity", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:mNrWkgRL2YcC", "citedby": "224"}, {"bib": {"title": "Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results", "year": "2002"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ufrVoPGSRksC", "citedby": "211"}, {"bib": {"title": "The next hurdle in cancer immunotherapy: Overcoming the non\u2013T-cell\u2013inflamed tumor microenvironment", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:uDGL6kOW6j0C", "citedby": "210"}, {"bib": {"title": "Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:a9-T7VOCCH8C", "citedby": "204"}, {"bib": {"title": "The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:0izLItjtcgwC", "citedby": "187"}, {"bib": {"title": "B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28", "year": "1998"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:NJ774b8OgUMC", "citedby": "183"}, {"bib": {"title": "Type I interferon response and innate immune sensing of cancer", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:lgwcVrK6X84C", "citedby": "178"}, {"bib": {"title": "Differential function of intestinal intraepithelial lymphocyte subsets.", "year": "1992"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:J_g5lzvAfSwC", "citedby": "177"}, {"bib": {"title": "Targeting the tumor microenvironment with interferon-\u03b2 bridges innate and adaptive immune responses", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:sA9dB-pw3HoC", "citedby": "176"}, {"bib": {"title": "Expression and function of CTLA-4 in Th1 and Th2 cells", "year": "1998"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:NMxIlDl6LWMC", "citedby": "176"}, {"bib": {"title": "Density of immunogenic antigens does not explain the presence or absence of the T-cell\u2013inflamed tumor microenvironment in melanoma", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:otzGkya1bYkC", "citedby": "173"}, {"bib": {"title": "The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:JV2RwH3_ST0C", "citedby": "172"}, {"bib": {"title": "Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:AXPGKjj_ei8C", "citedby": "171"}, {"bib": {"title": "B7DC/PDL2 promotes tumor immunity by a PD-1\u2013independent mechanism", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-nhnvRiOwuoC", "citedby": "171"}, {"bib": {"title": "Impact of oncogenic pathways on evasion of antitumour immune responses", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:vbGhcppDl1QC", "citedby": "168"}, {"bib": {"title": "Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways", "year": "1994"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:sszUF3NjhM4C", "citedby": "167"}, {"bib": {"title": "Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced \u2026", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:K3LRdlH-MEoC", "citedby": "166"}, {"bib": {"title": "\" Anergy\" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype.", "year": "1994"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LXmCCkuhhTsC", "citedby": "161"}, {"bib": {"title": "Defining the critical hurdles in cancer immunotherapy", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Zph67rFs4hoC", "citedby": "158"}, {"bib": {"title": "Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_B80troHkn4C", "citedby": "154"}, {"bib": {"title": "First-in-human phase I study of the oral inhibitor of indoleamine 2, 3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:DkZNVXde3BIC", "citedby": "151"}, {"bib": {"title": "Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:MLfJN-KU85MC", "citedby": "151"}, {"bib": {"title": "Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:MpfHP-DdYjUC", "citedby": "149"}, {"bib": {"title": "The host STING pathway at the interface of cancer and immunity", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LkGwnXOMwfcC", "citedby": "148"}, {"bib": {"title": "B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.", "year": "1996"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:M3ejUd6NZC8C", "citedby": "142"}, {"bib": {"title": "From defined human tumor antigens to effective immunization?", "year": "1995"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:e_rmSamDkqQC", "citedby": "136"}, {"bib": {"title": "Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:1Ye0OR6EYb4C", "citedby": "134"}, {"bib": {"title": "Molecular regulation of T\u2010cell anergy", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:xtoqd-5pKcoC", "citedby": "133"}, {"bib": {"title": "Innate immune signaling and regulation in cancer immunotherapy", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:YohjEiUPhakC", "citedby": "131"}, {"bib": {"title": "Molecular drivers of the non\u2013T-cell-inflamed tumor microenvironment in urothelial bladder cancer", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:L8Ckcad2t8MC", "citedby": "131"}, {"bib": {"title": "Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.", "year": "1996"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:1sJd4Hv_s6UC", "citedby": "127"}, {"bib": {"title": "Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.", "year": "1995"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kh2fBNsKQNwC", "citedby": "127"}, {"bib": {"title": "Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:j3f4tGmQtD8C", "citedby": "126"}, {"bib": {"title": "Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1", "year": "1999"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:gKiMpY-AVTkC", "citedby": "126"}, {"bib": {"title": "The STING pathway and the T cell-inflamed tumor microenvironment", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:L1USKYWJimsC", "citedby": "117"}, {"bib": {"title": "Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: variability and changes in tumor tissue over time", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:DBa1UEJaJKAC", "citedby": "114"}, {"bib": {"title": "CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_FxGoFyzp5QC", "citedby": "112"}, {"bib": {"title": "Negative regulation of T-cell function by PD-1", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:aIdbFUkbNIkC", "citedby": "107"}, {"bib": {"title": "B7. 1 is a quantitatively stronger costimulus than B7. 2 in the activation of naive CD8+ TCR-transgenic T cells", "year": "1998"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hMsQuOkrut0C", "citedby": "107"}, {"bib": {"title": "Spontaneous rejection of poorly immunogenic P1. HTR tumors by Stat6-deficient mice", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:CB2v5VPnA5kC", "citedby": "105"}, {"bib": {"title": "Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:0KyAp5RtaNEC", "citedby": "104"}, {"bib": {"title": "Phenotypic and functional analysis of murine CD3+, CD4-, CD8-TCR-gamma delta-expressing peripheral T cells.", "year": "1989"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Fu2w8maKXqMC", "citedby": "104"}, {"bib": {"title": "Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:aqlVkmm33-oC", "citedby": "103"}, {"bib": {"title": "Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1 \u2026", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:J-pR_7NvFogC", "citedby": "102"}, {"bib": {"title": "Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte \u2026", "year": "1988"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:r0BpntZqJG4C", "citedby": "100"}, {"bib": {"title": "Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.", "year": "1996"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:RGFaLdJalmkC", "citedby": "99"}, {"bib": {"title": "Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016; 6: 202\u2013216. doi: 10.1158/2159-8290"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:NhqRSupF_l8C", "citedby": "97"}, {"bib": {"title": "The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A\u2010encoded tumor antigen", "year": "1997"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:CaZNVDsoPx4C", "citedby": "96"}, {"bib": {"title": "Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:jFemdcug13IC", "citedby": "93"}, {"bib": {"title": "Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:TIZ-Mc8IlK0C", "citedby": "93"}, {"bib": {"title": "Epacadostat plus pembrolizumab versus pembrolizumab alone in patients with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HhcuHIWmDEUC", "citedby": "90"}, {"bib": {"title": "Murine hepatic accessory cells support the proliferation of Th1 but not Th2 helper T lymphocyte clones.", "year": "1989"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:XiSMed-E-HIC", "citedby": "90"}, {"bib": {"title": "Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:O0nohqN1r9EC", "citedby": "87"}, {"bib": {"title": "Cancer immunotherapy", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:l7t_Zn2s7bgC", "citedby": "85"}, {"bib": {"title": "Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:qxL8FJ1GzNcC", "citedby": "83"}, {"bib": {"title": "Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:OR75R8vi5nAC", "citedby": "82"}, {"bib": {"title": "Lymphatic vessels regulate immune microenvironments in human and murine melanoma", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:IaI1MmNe2tcC", "citedby": "80"}, {"bib": {"title": "Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:zA6iFVUQeVQC", "citedby": "80"}, {"bib": {"title": "Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide\u2010pulsed peripheral blood mononuclear cells by coadministration of recombinant \u2026", "year": "1999"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HtS1dXgVpQUC", "citedby": "80"}, {"bib": {"title": "Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:jU7OWUQzBzMC", "citedby": "79"}, {"bib": {"title": "Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4fGpz3EwCPoC", "citedby": "79"}, {"bib": {"title": "Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:7wO8s98CvbsC", "citedby": "79"}, {"bib": {"title": "Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes.", "year": "1993"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:BrOSOlqYqPUC", "citedby": "79"}, {"bib": {"title": "WNT/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:r_AWSJRzSzQC", "citedby": "78"}, {"bib": {"title": "Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152)", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:BwyfMAYsbu0C", "citedby": "77"}, {"bib": {"title": "Molecular pathways: targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:TlpoogIpr_IC", "citedby": "75"}, {"bib": {"title": "The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LgRImbQfgY4C", "citedby": "74"}, {"bib": {"title": "Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:zdjWy_NXXwUC", "citedby": "74"}, {"bib": {"title": "Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ClCfbGk0d_YC", "citedby": "73"}, {"bib": {"title": "Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double \u2026", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:AzKEL7Gb_04C", "citedby": "72"}, {"bib": {"title": "Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:5qfkUJPXOUwC", "citedby": "71"}, {"bib": {"title": "Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:8AbLer7MMksC", "citedby": "69"}, {"bib": {"title": "Interleukin\u201012\u2010secreting human papillomavirus type 16\u2013transformed cells provide a potent cancer vaccine that generates E7\u2010directed immunity", "year": "1999"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:QD3KBmkZPeQC", "citedby": "68"}, {"bib": {"title": "Induction of a cytolytic T\u2010cell response in mice with a recombinant adenovirus coding for tumor antigen P815A", "year": "1996"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:IsPWOBWtZBwC", "citedby": "68"}, {"bib": {"title": "Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:d1gkVwhDpl0C", "citedby": "67"}, {"bib": {"title": "Tumor-intrinsic oncogene pathways mediating immune avoidance", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:dTyEYWd-f8wC", "citedby": "66"}, {"bib": {"title": "Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: updated phase 1 results from ECHO-202/KEYNOTE-037", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:7H_MAutzIkAC", "citedby": "65"}, {"bib": {"title": "Antigen-specific blockade of T cells in vivo using dimeric MHC peptide", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:URolC5Kub84C", "citedby": "64"}, {"bib": {"title": "A new paradigm for tumor immune escape: \u03b2-catenin-driven immune exclusion", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:GnPB-g6toBAC", "citedby": "61"}, {"bib": {"title": "Rational combinations of immunotherapeutics that target discrete pathways", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WC23djZS0W4C", "citedby": "61"}, {"bib": {"title": "Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:mlAyqtXpCwEC", "citedby": "60"}, {"bib": {"title": "Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells", "year": "2002"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:7T2F9Uy0os0C", "citedby": "60"}, {"bib": {"title": "Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:dhFuZR0502QC", "citedby": "59"}, {"bib": {"title": "Antagonism of the STING pathway via activation of the AIM2 inflammasome by intracellular DNA", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:2P1L_qKh6hAC", "citedby": "59"}, {"bib": {"title": "Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A", "year": "1995"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:IUKN3-7HHlwC", "citedby": "58"}, {"bib": {"title": "Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1, 3-bis (2-chloroethyl)-1-nitrosourea in advanced melanoma", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:P7Ujq4OLJYoC", "citedby": "55"}, {"bib": {"title": "Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG (-/-) mice.", "year": "1997"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:TQgYirikUcIC", "citedby": "55"}, {"bib": {"title": "Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:gsN89kCJA0AC", "citedby": "54"}, {"bib": {"title": "Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:3fE2CSJIrl8C", "citedby": "53"}, {"bib": {"title": "Tumor and host factors controlling antitumor immunity and efficacy of cancer immunotherapy", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4vMrXwiscB8C", "citedby": "52"}, {"bib": {"title": "Phase 2 study of RO 4929097, a gamma\u2010secretase inhibitor, in metastatic melanoma: SWOG 0933", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-mN3Mh-tlDkC", "citedby": "52"}, {"bib": {"title": "A designer ligand specific for Kv1. 3 channels from a scorpion neurotoxin-based library", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:yqoGN6RLRZoC", "citedby": "52"}, {"bib": {"title": "Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:eflP2zaiRacC", "citedby": "52"}, {"bib": {"title": "Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:PoWvk5oyLR8C", "citedby": "51"}, {"bib": {"title": "Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted \u2026", "year": "1990"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_Re3VWB3Y0AC", "citedby": "51"}, {"bib": {"title": "Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HGTzPopzzJcC", "citedby": "50"}, {"bib": {"title": "NK cells restrain spontaneous antitumor CD8+ T cell priming through PD-1/PD-L1 interactions with dendritic cells", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:8Xgff_V0N9gC", "citedby": "50"}, {"bib": {"title": "Therapeutic activity of high-dose intratumoral IFN-\u03b2 requires direct effect on the tumor vasculature", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:gVv57TyPmFsC", "citedby": "50"}, {"bib": {"title": "Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:8k81kl-MbHgC", "citedby": "50"}, {"bib": {"title": "Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ziOE8S1-AIUC", "citedby": "50"}, {"bib": {"title": "The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response.", "year": "1999"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SdhP9T11ey4C", "citedby": "49"}, {"bib": {"title": "Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:bFI3QPDXJZMC", "citedby": "48"}, {"bib": {"title": "Innate immune sensing of cancer: clues from an identified role for type I IFNs", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_Qo2XoVZTnwC", "citedby": "47"}, {"bib": {"title": "A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:L7CI7m0gUJcC", "citedby": "46"}, {"bib": {"title": "1214OEpacadostat plus pembrolizumab in patients with advanced melanoma: phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:zCSUwVk65WsC", "citedby": "45"}, {"bib": {"title": "Immunotherapy of head and neck cancer: emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HJSXoJQnj-YC", "citedby": "45"}, {"bib": {"title": "CD40 ligation reverses T cell tolerance in acute myeloid leukemia", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:nZcligLrVowC", "citedby": "45"}, {"bib": {"title": "Control of T lymphocyte signal transduction through clonal anergy", "year": "1996"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:9pM33mqn1YgC", "citedby": "45"}, {"bib": {"title": "The composition of the microbiota modulates allograft rejection", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:rmuvC79q63oC", "citedby": "44"}, {"bib": {"title": "Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kNdYIx-mwKoC", "citedby": "44"}, {"bib": {"title": "Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12-but not B7-1-transfected tumor cells.", "year": "1997"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:N5tVd3kTz84C", "citedby": "44"}, {"bib": {"title": "Differential requirement for protein tyrosine kinase Fyn in the functional activation of antigen-specific T lymphocyte clones through the TCR or Thy-1.", "year": "1995"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:qwy9JoKyICEC", "citedby": "44"}, {"bib": {"title": "Future perspectives in melanoma research. Meeting report from the \u201cMelanoma Bridge. Napoli, December 2nd-4th 2012\u201d", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:zGdJYJv2LkUC", "citedby": "43"}, {"bib": {"title": "Intratumoral CD8+ T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:JTqpx9DYBaYC", "citedby": "42"}, {"bib": {"title": "New perspectives on type I IFNs in cancer", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:JQOojiI6XY0C", "citedby": "42"}, {"bib": {"title": "Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SpbeaW3--B0C", "citedby": "42"}, {"bib": {"title": "Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:pyW8ca7W8N0C", "citedby": "42"}, {"bib": {"title": "Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:35N4QoGY0k4C", "citedby": "42"}, {"bib": {"title": "Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:dQ2og3OwTAUC", "citedby": "42"}, {"bib": {"title": "Molecular profiling of melanoma and the evolution of patient-specific therapy", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kuK5TVdYjLIC", "citedby": "41"}, {"bib": {"title": "Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:EkHepimYqZsC", "citedby": "41"}, {"bib": {"title": "CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin 4-producing T helper cell type 2 subset.", "year": "1990"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WHdLCjDvYFkC", "citedby": "41"}, {"bib": {"title": "Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2, 3-dioxygenase (IDO1) INCB024360 in patients (pts) with \u2026", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:YFjsv_pBGBYC", "citedby": "40"}, {"bib": {"title": "Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:yB1At4FlUx8C", "citedby": "39"}, {"bib": {"title": "Differential activation of murine TH1 and TH2 clones", "year": "1991"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:vV6vV6tmYwMC", "citedby": "39"}, {"bib": {"title": "On the TRAIL Toward Death Receptor\u2013Based Cancer Therapeutics", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:rbm3iO8VlycC", "citedby": "38"}, {"bib": {"title": "Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:q-HalDI95KYC", "citedby": "38"}, {"bib": {"title": "Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:lmc2jWPfTJgC", "citedby": "38"}, {"bib": {"title": "Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:6bLC7aUMtPcC", "citedby": "36"}, {"bib": {"title": "Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Mojj43d5GZwC", "citedby": "36"}, {"bib": {"title": "Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4hFrxpcac9AC", "citedby": "35"}, {"bib": {"title": "A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:5nxA0vEk-isC", "citedby": "35"}, {"bib": {"title": "Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:sSrBHYA8nusC", "citedby": "35"}, {"bib": {"title": "\u03b2-Catenin inhibits T cell activation by selective interference with linker for activation of T cells\u2013phospholipase C-\u03b31 phosphorylation", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:rHJHxKgnXwkC", "citedby": "35"}, {"bib": {"title": "Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_OXeSy2IsFwC", "citedby": "34"}, {"bib": {"title": "Exploring the emerging role of the microbiome in cancer immunotherapy", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:NxmKEeNBbOMC", "citedby": "33"}, {"bib": {"title": "Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:v1_lew4L6wgC", "citedby": "33"}, {"bib": {"title": "Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Ade32sEp0pkC", "citedby": "32"}, {"bib": {"title": "The expanding universe of regulatory T cell subsets in cancer", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:mB3voiENLucC", "citedby": "31"}, {"bib": {"title": "Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-\u03b3-producing T cells", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:mUJArPsKIAAC", "citedby": "31"}, {"bib": {"title": "Production of TH1 and TH2 Cell Lines and Clones", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:PaBasH6fAo0C", "citedby": "30"}, {"bib": {"title": "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:cWzG1nlazyYC", "citedby": "29"}, {"bib": {"title": "511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:5bg8sr1QxYwC", "citedby": "29"}, {"bib": {"title": "Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:738O_yMBCRsC", "citedby": "29"}, {"bib": {"title": "\u03b2-catenin does not regulate memory T cell phenotype", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:DJbcl8HfkQkC", "citedby": "29"}, {"bib": {"title": "Death of peripheral CD8+ T\u2004cells in the absence of MHC class\u2004I is Fas\u2010dependent and not blocked by Bcl\u2010xL", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:A8cqit5AE6sC", "citedby": "29"}, {"bib": {"title": "CD28 is not required for c-Jun N-terminal kinase activation in T cells", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:fPk4N6BV_jEC", "citedby": "29"}, {"bib": {"title": "Brain tumor microenvironment and host state: Implications for immunotherapy", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:QYdC8u9Cj1oC", "citedby": "28"}, {"bib": {"title": "Treatment of cancer by manipulation of commensal microflora", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:70eg2SAEIzsC", "citedby": "28"}, {"bib": {"title": "Correlation of WNT/\u03b2-catenin pathway activation with immune exclusion across most human cancers.", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SP6oXDckpogC", "citedby": "28"}, {"bib": {"title": "Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma.", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HeT0ZceujKMC", "citedby": "28"}, {"bib": {"title": "SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools-a compass in the land of biomarker discovery", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:rO6llkc54NcC", "citedby": "28"}, {"bib": {"title": "ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Dem6FJhTUoYC", "citedby": "28"}, {"bib": {"title": "Phase Ib study of vemurafenib in combination with the MEK inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7)", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:s85pQhAUCrAC", "citedby": "27"}, {"bib": {"title": "Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:O3NaXMp0MMsC", "citedby": "26"}, {"bib": {"title": "Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), in advanced cancer patients.", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4xDN1ZYqzskC", "citedby": "26"}, {"bib": {"title": "Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:tkaPQYYpVKoC", "citedby": "26"}, {"bib": {"title": "Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity", "year": "2002"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:xtRiw3GOFMkC", "citedby": "26"}, {"bib": {"title": "Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:wKETBy42zhYC", "citedby": "25"}, {"bib": {"title": "Transplantation and the CD28/CTLA4/B7 pathway", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:KbBQZpvPDL4C", "citedby": "25"}, {"bib": {"title": "Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:PYBJJbyH-FwC", "citedby": "23"}, {"bib": {"title": "Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways.", "year": "1987"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:3htObqc8RwsC", "citedby": "22"}, {"bib": {"title": "Diagnosis and treatment of mycoplasma\u2010contaminated cell cultures", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hFOr9nPyWt4C", "citedby": "21"}, {"bib": {"title": "Metabolic mechanisms of tumor resistance to T cell effector function", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:XoXfffV-tXoC", "citedby": "21"}, {"bib": {"title": "Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell\u2010based vaccines", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:UHK10RUVsp4C", "citedby": "21"}, {"bib": {"title": "Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:wvYxNZNCP7wC", "citedby": "20"}, {"bib": {"title": "An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:lSLTfruPkqcC", "citedby": "20"}, {"bib": {"title": "Innovations and challenges in melanoma: summary statement from the first Cambridge conference", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:v6i8RKmR8ToC", "citedby": "20"}, {"bib": {"title": "A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:qUcmZB5y_30C", "citedby": "20"}, {"bib": {"title": "CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:3NQIlFlcGxIC", "citedby": "20"}, {"bib": {"title": "Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide", "year": "1999"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LhH-TYMQEocC", "citedby": "20"}, {"bib": {"title": "Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof", "year": "1997"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:mWEH9CqjF64C", "citedby": "20"}, {"bib": {"title": "Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Tyk-4Ss8FVUC", "citedby": "19"}, {"bib": {"title": "A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in \u2026", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:OU6Ihb5iCvQC", "citedby": "18"}, {"bib": {"title": "T cell development and function in CrkL\u2010deficient mice", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:__bU50VfleQC", "citedby": "18"}, {"bib": {"title": "Vaccine adjuvants for immunotherapy of melanoma", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ALROH1vI_8AC", "citedby": "18"}, {"bib": {"title": "A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma \u2026", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:uVUOdF_882EC", "citedby": "17"}, {"bib": {"title": "Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer.", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hCrLmN-GePgC", "citedby": "17"}, {"bib": {"title": "Vemurafenib (VEM) and MEK inhibitor, cobimetinib (GDC-0973), in advanced BRAFV600-mutated melanoma (BRIM7): dose-escalation and expansion results of a phase IB study", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:AYInfyleIOsC", "citedby": "17"}, {"bib": {"title": "FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the \u201cMelanoma Research: a bridge from Naples to the World. Napoli, December 5 th\u20136 th 2011\u201d", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-7ulzOJl1JYC", "citedby": "17"}, {"bib": {"title": "Production of T cell clones", "year": "1997"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:QIV2ME_5wuYC", "citedby": "17"}, {"bib": {"title": "T cell-NF-\u03baB activation is required for tumor control in vivo", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:P5F9QuxV20EC", "citedby": "16"}, {"bib": {"title": "Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kF1pexMAQbMC", "citedby": "16"}, {"bib": {"title": "Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:6_hjMsCP8ZoC", "citedby": "16"}, {"bib": {"title": "Chemokines expressed in melanoma metastases associated with T cell infiltration", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:B3FOqHPlNUQC", "citedby": "16"}, {"bib": {"title": "Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ruyezt5ZtCIC", "citedby": "16"}, {"bib": {"title": "Temozolomide for melanoma: new toxicities and new opportunities", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:buQ7SEKw-1sC", "citedby": "16"}, {"bib": {"title": "Rational development of tumour antigen-specific immunization in melanoma.", "year": "1995"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ce2CqMG-AY4C", "citedby": "16"}, {"bib": {"title": "Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab+ nivolumab", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:vRqMK49ujn8C", "citedby": "15"}, {"bib": {"title": "A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:eGYfIraVYiQC", "citedby": "15"}, {"bib": {"title": "Homeostatic proliferation of na\u00efve CD8+ T cells depends on CD62L/L\u2010selectin\u2010mediated homing to peripheral LN", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Y0pCki6q_DkC", "citedby": "15"}, {"bib": {"title": "Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:b0M2c_1WBrUC", "citedby": "15"}, {"bib": {"title": "Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a \u2026", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:V3AGJWp-ZtQC", "citedby": "14"}, {"bib": {"title": "Cancer immunotherapy", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:k_7cPK9k7w8C", "citedby": "14"}, {"bib": {"title": "Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients \u2026", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hSRAE-fF4OAC", "citedby": "14"}, {"bib": {"title": "A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:uLbwQdceFCQC", "citedby": "14"}, {"bib": {"title": "Vaccine adjuvants for immunotherapy of melanoma", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4MWp96NkSFoC", "citedby": "14"}, {"bib": {"title": "Mechanisms of tumor cell\u2013intrinsic immune evasion", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:9ZlFYXVOiuMC", "citedby": "13"}, {"bib": {"title": "Treatment of cancer by manipulation of commensal microflora", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ubry08Y2EpUC", "citedby": "13"}, {"bib": {"title": "Future perspectives in melanoma research: meeting report from the\" Melanoma Bridge\", Napoli, December 5th-8th 2013", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:2tRrZ1ZAMYUC", "citedby": "13"}, {"bib": {"title": "Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:0EnyYjriUFMC", "citedby": "13"}, {"bib": {"title": "A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:eJXPG6dFmWUC", "citedby": "13"}, {"bib": {"title": "Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof", "year": "1998"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4JMBOYKVnBMC", "citedby": "13"}, {"bib": {"title": "Liver of MRL/lpr mice contain interleukin\u20104\u2010producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones", "year": "1992"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:foquWX3nUaYC", "citedby": "13"}, {"bib": {"title": "Improving efficacy and safety of agonistic anti-CD40 antibody through extracellular matrix affinity", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_Ybze24A_UAC", "citedby": "12"}, {"bib": {"title": "Density of immunogenic antigens and presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma.", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:RHpTSmoSYBkC", "citedby": "12"}, {"bib": {"title": "Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:nVrZBo8bIpAC", "citedby": "12"}, {"bib": {"title": "Ocular melanoma metastasis to the cervical spine", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:a3BOlSfXSfwC", "citedby": "12"}, {"bib": {"title": "The p815 mastocytoma tumor model", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:1tZ8xJnm2c8C", "citedby": "12"}, {"bib": {"title": "The microbiota: a new variable impacting cancer treatment outcomes", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:u_35RYKgDlwC", "citedby": "11"}, {"bib": {"title": "Future perspectives in melanoma research: meeting report from the \u201cMelanoma Bridge\u201d: Napoli, December 3rd\u20136th 2014", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WAzi4Gm8nLoC", "citedby": "11"}, {"bib": {"title": "Efficacy and safety of ipilimumab in patients with advanced melanoma who had progressed on one or more prior therapies: results from a single-arm, multicenter study", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:BUYA1_V_uYcC", "citedby": "11"}, {"bib": {"title": "Peripheral survival of na\u00efve CD8+ T cells", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:tHtfpZlB6tUC", "citedby": "11"}, {"bib": {"title": "STING pathway agonism as a cancer therapeutic", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4aZ_i-5WJEQC", "citedby": "10"}, {"bib": {"title": "Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:q3oQSFYPqjQC", "citedby": "10"}, {"bib": {"title": "Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:NDuN12AVoxsC", "citedby": "10"}, {"bib": {"title": "Melanoma-intrinsic \u03b2-catenin signaling prevents T cell infiltration and anti-tumor immunity", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:T_ojBgVMvoEC", "citedby": "10"}, {"bib": {"title": "Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:VOx2b1Wkg3QC", "citedby": "10"}, {"bib": {"title": "Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:TFP_iSt0sucC", "citedby": "10"}, {"bib": {"title": "Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:wE-fMHVdjMkC", "citedby": "10"}, {"bib": {"title": "Panels of molecular targets differentially expressed during CD8+ T cell priming, and methods for therapy and diagnosis utilizing the same", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:FAceZFleit8C", "citedby": "10"}, {"bib": {"title": "Regulation of anti-immunoglobulin-induced B lymphoma growth arrest by transforming growth factor \u03b21 and dexamethasone", "year": "1991"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:CdxZDUztZiMC", "citedby": "10"}, {"bib": {"title": "Evidence implicating I region-restricted antigen presentation in alloantigen and nominal antigen recognition by a dual-reactive helper T lymphocyte clone.", "year": "1984"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Z5m8FVwuT1cC", "citedby": "10"}, {"bib": {"title": "Synergistic combination of immunologic inhibitors for the treatment of cancer", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Wp0gIr-vW9MC", "citedby": "9"}, {"bib": {"title": "Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma.", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:OcBU2YAGkTUC", "citedby": "9"}, {"bib": {"title": "Unlocking tumor vascular barriers with CXCR3: implications for cancer immunotherapy", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:QyXJ3EUuO1IC", "citedby": "9"}, {"bib": {"title": "Cutting edge: engineering active IKK\u03b2 in T cells drives tumor rejection", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:dfsIfKJdRG4C", "citedby": "9"}, {"bib": {"title": "Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:An6A6Jpfc1oC", "citedby": "9"}, {"bib": {"title": "Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2, 3-dioxygenase and programmed death ligand 1.", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:w0F2JDEymm0C", "citedby": "9"}, {"bib": {"title": "Biochemical Analysis of Activated T Lymphocytes", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:dshw04ExmUIC", "citedby": "9"}, {"bib": {"title": "Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:mvPsJ3kp5DgC", "citedby": "8"}, {"bib": {"title": "Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:UxriW0iASnsC", "citedby": "8"}, {"bib": {"title": "Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:VL0QpB8kHFEC", "citedby": "8"}, {"bib": {"title": "31st annual meeting and associated programs of the Society for Immunotherapy of cancer (SITC 2016): late breaking abstracts", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-_dYPAW6P2MC", "citedby": "8"}, {"bib": {"title": "Melanoma and immunotherapy bridge 2015", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:F1b5ZUV5XREC", "citedby": "8"}, {"bib": {"title": "24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:DrR-2ekChdkC", "citedby": "8"}, {"bib": {"title": "Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer.", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:7Hz3ACDFbsoC", "citedby": "8"}, {"bib": {"title": "A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Hck25ST_3aIC", "citedby": "8"}, {"bib": {"title": "Targeted therapeutics in melanoma", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:0N-VGjzr574C", "citedby": "8"}, {"bib": {"title": "Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:bz8QjSJIRt4C", "citedby": "7"}, {"bib": {"title": "The HLA\u2010A2\u2010restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:tOudhMTPpwUC", "citedby": "7"}, {"bib": {"title": "Secondary resistance to immunotherapy associated with \u03b2-catenin pathway activation or PTEN loss in metastatic melanoma", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hGdtkIFZdKAC", "citedby": "6"}, {"bib": {"title": "Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:zwpXiJ37cpgC", "citedby": "6"}, {"bib": {"title": "Distinct graft-specific TCR avidity profiles during acute rejection and tolerance", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:QsaTk4IG4EwC", "citedby": "6"}, {"bib": {"title": "Fast forward\u2014neoadjuvant cancer immunotherapy", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:FiytvqdAVhgC", "citedby": "6"}, {"bib": {"title": "Manipulating the microbiome to improve the efficacy of immunotherapy.", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:8xutWZnSdmoC", "citedby": "6"}, {"bib": {"title": "A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:MAUkC_7iAq8C", "citedby": "6"}, {"bib": {"title": "Phase 2 trial of talabostat in stage IV melanoma", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:MIg0yeAD4ggC", "citedby": "6"}, {"bib": {"title": "Diagnosis and treatment of mycoplasma\u2010contaminated cell cultures", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:cFHS6HbyZ2cC", "citedby": "6"}, {"bib": {"title": "High-throughput stability screening of neoantigen/HLA complexes improves immunogenicity predictions", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:tS2w5q8j5-wC", "citedby": "5"}, {"bib": {"title": "Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with \u2026", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:PELIpwtuRlgC", "citedby": "5"}, {"bib": {"title": "Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:anf4URPfarAC", "citedby": "5"}, {"bib": {"title": "Patterns of CD8+ T-cell infiltration and immune escape mechanisms in head and neck cancer.", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:unp9ATQDT5gC", "citedby": "5"}, {"bib": {"title": "Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:blknAaTinKkC", "citedby": "5"}, {"bib": {"title": "Melanoma presenting as circulating tumor cells associated with failed angiogenesis", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:BzfGm06jWhQC", "citedby": "5"}, {"bib": {"title": "Digital electronic audio player with cassette tape simulation feature and compatible with cassette tape players, and method therefore", "year": "2002"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:pS0ncopqnHgC", "citedby": "5"}, {"bib": {"title": "Integrating IL-12 into therapeutic cancer vaccines.", "year": "2002"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kw52XkFRtyQC", "citedby": "5"}, {"bib": {"title": "Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:2vr6o8x5NLkC", "citedby": "4"}, {"bib": {"title": "Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November\u20132 December, 2017, Naples, Italy)", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kRWSkSYxWN8C", "citedby": "4"}, {"bib": {"title": "A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:5MTHONV0fEkC", "citedby": "4"}, {"bib": {"title": "SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kWvqk_afx_IC", "citedby": "4"}, {"bib": {"title": "Methods and compositions related to T-cell activity", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:BqipwSGYUEgC", "citedby": "4"}, {"bib": {"title": "Back from the dead: TIL apoptosis in cancer immune evasion", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:X9ykpCP0fEIC", "citedby": "4"}, {"bib": {"title": "Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-\u03b12b in patients with metastatic melanoma", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:yFnVuubrUp4C", "citedby": "4"}, {"bib": {"title": "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_FM0Bhl9EiAC", "citedby": "4"}, {"bib": {"title": "MYC\u2014a thorn in the side of cancer immunity", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:1lhNe0rCu4AC", "citedby": "4"}, {"bib": {"title": "Transcriptional profiling of melanoma as a potential predictive biomarker for response to immunotherapy", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:BJbdYPG6LGMC", "citedby": "4"}, {"bib": {"title": "Protein kinase C\u03b8 focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-FonjvnnhkoC", "citedby": "4"}, {"bib": {"title": "T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:mVmsd5A6BfQC", "citedby": "4"}, {"bib": {"title": "Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:AHdEip9mkN0C", "citedby": "4"}, {"bib": {"title": "Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ghEM2AJqZyQC", "citedby": "4"}, {"bib": {"title": "Cells of the monocyte/macrophage lineage", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:p__nRnzSRKYC", "citedby": "4"}, {"bib": {"title": "WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:W7OEmFMy1HYC", "citedby": "3"}, {"bib": {"title": "Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab in patients with melanoma WHO progressed during prior anti-PD-1/PD \u2026", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Se3iqnhoufwC", "citedby": "3"}, {"bib": {"title": "Innate Immune Sensing in Anti-Tumor Immunity and Cancer Immunotherapy", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Ug5p-4gJ2f0C", "citedby": "3"}, {"bib": {"title": "Use of sting agonist as cancer treatment", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ldfaerwXgEUC", "citedby": "3"}, {"bib": {"title": "Density of immunogenic antigens does not explain presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ML0RJ9NH7IQC", "citedby": "3"}, {"bib": {"title": "Effect of melanoma intrinsic \u03b2-catenin signaling on immune exclusion and resistance to immunotherapies.", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LI9QrySNdTsC", "citedby": "3"}, {"bib": {"title": "Vemurafenib and Cobimetinib Potently Inhibit Ps6 Signaling in Brafv600 Mutation\u2013Positive Locally Advanced or Metastatic Melanoma from Brim7 Study", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Xz60mAmATU4C", "citedby": "3"}, {"bib": {"title": "Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF V600-mutated melanoma (BRIM7)", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:UmS_249rOGwC", "citedby": "3"}, {"bib": {"title": "An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:7PzlFSSx8tAC", "citedby": "3"}, {"bib": {"title": "A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic \u2026", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:isC4tDSrTZIC", "citedby": "3"}, {"bib": {"title": "Review of the 25 th annual scientific meeting of the International Society for Biological Therapy of Cancer", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:RJOyoaXV5v8C", "citedby": "3"}, {"bib": {"title": "Phase II study of the src family kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Xl6nMSl579sC", "citedby": "3"}, {"bib": {"title": "Beta-catenin negatively regulates peripheral T cell activation (35.36)", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HIFyuExEbWQC", "citedby": "3"}, {"bib": {"title": "An adenoviral vector for probing promoter activity in primary immune cells", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ye4kPcJQO24C", "citedby": "3"}, {"bib": {"title": "Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:BmWJbWwHJAwC", "citedby": "2"}, {"bib": {"title": "Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th\u20131 December 1st, 2018, Naples, Italy)", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:KWzIFqRkAKkC", "citedby": "2"}, {"bib": {"title": "Correlation of constitutive PD-1 resistance in HNC with GM-CSF expression and presence of myeloid derived suppressor cells (MDSCs).", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:EsEWqaRxkBgC", "citedby": "2"}, {"bib": {"title": "Identification of T-cell-inflamed gastric adenocarcinoma in The Cancer Genome Atlas (TCGA).", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:abG-DnoFyZgC", "citedby": "2"}, {"bib": {"title": "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:W5xh706n7nkC", "citedby": "2"}, {"bib": {"title": "Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib combined with vemurafenib in BRAF (V600)-mutant melanoma", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LPZeul_q3PIC", "citedby": "2"}, {"bib": {"title": "Abstract SY39-02: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:XD-gHx7UXLsC", "citedby": "2"}, {"bib": {"title": "Molecular characterization of immune exclusion in small-cell lung cancer.", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:D03iK_w7-QYC", "citedby": "2"}, {"bib": {"title": "Correlation of specific genetic aberrations and signaling pathways with T-cell inflamed phenotype (TCIP) in head and neck cancer and as novel candidate biomarkers for \u2026", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Bg7qf7VwUHIC", "citedby": "2"}, {"bib": {"title": "Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:nRpfm8aw39MC", "citedby": "2"}, {"bib": {"title": "Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ZuybSZzF8UAC", "citedby": "2"}, {"bib": {"title": "Autophagy in tumor cells and the host STING pathway are critical for innate immune sensing of tumors and bridging to an adaptive immune response (P2183)", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:uc_IGeMz5qoC", "citedby": "2"}, {"bib": {"title": "Results of phase 1B combined BRAF and MEK inhibition with vemurafenib (vem) and GDC-0973 in patients (pts) with BRAFV600 advanced melanoma and establishing a phase III dose", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:NMlhSUseqAsC", "citedby": "2"}, {"bib": {"title": "The Wnt/GSK3/\u03b2-catenin signaling pathway regulates CD8+ T cell effector functions", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_xSYboBqXhAC", "citedby": "2"}, {"bib": {"title": "Lymphoma-infiltrating immune cells.", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:35r97b3x0nAC", "citedby": "2"}, {"bib": {"title": "Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ZeXyd9-uunAC", "citedby": "2"}, {"bib": {"title": "Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:0aBXIfxlw9sC", "citedby": "2"}, {"bib": {"title": "Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors.", "year": "1988"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:i2xiXl-TujoC", "citedby": "2"}, {"bib": {"title": "Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-\u03b3-signaling mutant cancer cells", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:c_xDhezhKKUC", "citedby": "1"}, {"bib": {"title": "A case of dual-mechanism hematologic immune-related adverse event in a patient with metastatic melanoma treated with combined nivolumab and ipilimumab", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:zUl2_INMlC4C", "citedby": "1"}, {"bib": {"title": "Treatment of cancer by manipulation of commensal microflora", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:H_jBuBxbQIAC", "citedby": "1"}, {"bib": {"title": "Safety and clinical activity of pembrolizumab immunotherapy and multi-organ site ablative stereotactic body radiotherapy (iMOSART) in patients with advanced solid tumors.", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:mKu_rENv82IC", "citedby": "1"}, {"bib": {"title": "Immunogenomic analyses of tumor cells and microenvironment in patients with advanced melanoma before and after treatment with nivolumab", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:2osOgNQ5qMEC", "citedby": "1"}, {"bib": {"title": "Manipulating innate immune pathways as cancer immunotherapy", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WZBGuue-350C", "citedby": "1"}, {"bib": {"title": "A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:jgBuDB5drN8C", "citedby": "1"}, {"bib": {"title": "WT1 peptide vaccine is able to induce WT1-specifc immune response with TCR clonal enrichment to control minimal residual disease in patients with myeloid leukemia", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:silx2ntsSuwC", "citedby": "1"}, {"bib": {"title": "Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced \u2026", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:cK4Rrx0J3m0C", "citedby": "1"}, {"bib": {"title": "Use of sting agonist as cancer treatment", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:q3CdL3IzO_QC", "citedby": "1"}, {"bib": {"title": "Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HE397vMXCloC", "citedby": "1"}, {"bib": {"title": "A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:OBSaB-F7qqsC", "citedby": "1"}, {"bib": {"title": "Germ Warfare.", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:NXb4pA-qfm4C", "citedby": "1"}, {"bib": {"title": "LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:eAlLMO4JVmQC", "citedby": "1"}, {"bib": {"title": "The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:sJsF-0ZLhtgC", "citedby": "1"}, {"bib": {"title": "Fyn Expression Predicates Both Protective Immunity and Onset of Autoimmunity", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_5tno0g5mFcC", "citedby": "1"}, {"bib": {"title": "Biomarker analysis of on-treatment and at progression biopsies from BRIM7-a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:FiDNX6EVdGUC", "citedby": "1"}, {"bib": {"title": "Primary Murine CD4+ T Cells Fail to Acquire the Ability to Produce Effector Cytokines When Active Ras Is Present during Th1/Th2 Differentiation", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LPtt_HFRSbwC", "citedby": "1"}, {"bib": {"title": "Future perspectives in melanoma research: meeting report from the", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4DMP91E08xMC", "citedby": "1"}, {"bib": {"title": "Therapeutic efficacy of combined blockade of CTLA-4+/-PD-L1+/-IDO is associated with re-activation of T cells directly within the tumor microenvironment", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:KUbvn5osdkgC", "citedby": "1"}, {"bib": {"title": "Phase II trial of RO4929097 Notch gamma-secretase inhibitor in metastatic melanoma: SWOG S0933.", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:KxtntwgDAa4C", "citedby": "1"}, {"bib": {"title": "Randomized phase II trial of multipeptide vaccination with or without a single pre-vaccine dose of denileukin diftitox in advanced melanoma.", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:eQOLeE2rZwMC", "citedby": "1"}, {"bib": {"title": "Harnessing the immune response.", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:maZDTaKrznsC", "citedby": "1"}, {"bib": {"title": "The melanoma tumor microenvironment as a predictive biomarker for response to immunotherapies", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:z6xuaG2dYH0C", "citedby": "1"}, {"bib": {"title": "Vaccination with class I and II tumor peptide-loaded, cocktail-matured monocyte-derived DCs demonstrates solid immunogenicity and prolonged survival in a subset of melanoma \u2026", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:qjMakFHDy7sC", "citedby": "1"}, {"bib": {"title": "Overall Survival (OS) and New Patterns of Response in Patients (Pts) With Advanced Melanoma Treated With Ipilimumab", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:65Yg0jNCQDAC", "citedby": "1"}, {"bib": {"title": "Insights into mechanisms of immune resistance in the tumor microenvironment through molecular profiling", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:OTTXONDVkokC", "citedby": "1"}, {"bib": {"title": "A phase 2 study of talabostat in patients with stage IV melanoma", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:69ZgNCALVd0C", "citedby": "1"}, {"bib": {"title": "Reciprocal expression of indoleamine-2, 3-dioxygenase (IDO) and arginase-I in metastatic melanoma tumors", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:IjCSPb-OGe4C", "citedby": "1"}, {"bib": {"title": "A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin in patients with renal cell carcinoma", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:XiVPGOgt02cC", "citedby": "1"}, {"bib": {"title": "Update on vaccines for solid tumors.", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:BrmTIyaxlBUC", "citedby": "1"}, {"bib": {"title": "Regulation of T Lymphocyte Responses: Interactions among Receptors", "year": "1989"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:eq2jaN3J8jMC", "citedby": "1"}, {"bib": {"title": "Anti-proliferative effect of IFN-\u03b3 in immune regulation. I. IFN-\u03b3 inhibits the proliferation of T_< h1> murine helper T lymphocyte clones.", "year": "1988"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:artPoR2Yc-kC", "citedby": "1"}, {"bib": {"title": "Tumor and host factors regulating antitumor immunity and immunotherapy efficacy.", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:wUn16MOA3RoC", "citedby": "0"}, {"bib": {"title": "Abstract IA06: Tumor and host factors regulating antitumor immunity and immunotherapy efficacy", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:wSy_KLzO7YEC", "citedby": "0"}, {"bib": {"title": "ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:nqdriD65xNoC", "citedby": "0"}, {"bib": {"title": "Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:dAp6zn-oMfAC", "citedby": "0"}, {"bib": {"title": "Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:iyewoVqAXLQC", "citedby": "0"}, {"bib": {"title": "A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ijdKiLOsEJMC", "citedby": "0"}, {"bib": {"title": "PAK4 as a cancer immune-evasion target", "year": "2020"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_AeoHAGD03cC", "citedby": "0"}, {"bib": {"title": "Immune selection for IFN-gamma signaling mutant cancer cells involves tumor heterogeneity and clonal cooperation", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:nPT8s1NX_-sC", "citedby": "0"}, {"bib": {"title": "Enhancing IFN-beta production through synergy between the STING and TLR pathways", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hQUaER0FWQ4C", "citedby": "0"}, {"bib": {"title": "Evidence that a germline genetic variant impairs a robust anti-tumor immune response in a substrain of C57BL/6 mice", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:oPLKW5k6eA4C", "citedby": "0"}, {"bib": {"title": "Tumor cell-intrinsic defects in STING pathway signaling and IFN-beta gene regulation", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LGlY6t8CeOMC", "citedby": "0"}, {"bib": {"title": "Patient-derived microbiota germ-free mouse model for identifying mechanisms of checkpoint blockade efficacy modulation", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:YTuZlYwrTOUC", "citedby": "0"}, {"bib": {"title": "Variation in the commensal urinary microbiome is associated with response to Bacillus Calmette-Guerin (BCG) immunotherapy in early stage urothelial bladder cancer", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:t-hv7AR41mYC", "citedby": "0"}, {"bib": {"title": "SY7-1 TUMOR AND HOST FACTORS REGULATING ANTI-TUMOR IMMUNITY AND IMMUNOTHERAPY EFFICACY", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:G1UMdFYMoxkC", "citedby": "0"}, {"bib": {"title": "The commensal urinary microbiome as a predictor of response to Bacillus Calmette-Guerin (BCG) immunotherapy in non-muscle invasive bladder cancer", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-uzm3Y7AvW0C", "citedby": "0"}, {"bib": {"title": "Multichannel immunofluorescence imaging to assess the immune composition of tumor microenvironment in bladder cancer", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ZqE1mSdD_DYC", "citedby": "0"}, {"bib": {"title": "Epacadostat Plus Pembrolizumab versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma: Results of the Phase 3, Randomised, Double-Blind Echo-301 \u2026", "year": "2019"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-DxkuPiZhfEC", "citedby": "0"}, {"bib": {"title": "Synergistic combination of immunologic inhibitors for the treatment of cancer", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:UeHWp8X0CEIC", "citedby": "0"}, {"bib": {"title": "Tumor and host factors regulating anti-tumor immunity and immotherapy efficacy", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:g5m5HwL7SMYC", "citedby": "0"}, {"bib": {"title": "Methods and compositions related to t-cell activity", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:EYYDruWGBe4C", "citedby": "0"}, {"bib": {"title": "Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:RuPIJ_LgqDgC", "citedby": "0"}, {"bib": {"title": "OA05. 02 Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:PkcyUWeTMh0C", "citedby": "0"}, {"bib": {"title": "Perspectives in melanoma", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:vDijr-p_gm4C", "citedby": "0"}, {"bib": {"title": "Genomic drivers of cancer are enriched and mutually exclusive within non-T cell-inflamed tumors", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LjlpjdlvIbIC", "citedby": "0"}, {"bib": {"title": "Beta-catenin inhibitors in cancer immunotherapy", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ODE9OILHJdcC", "citedby": "0"}, {"bib": {"title": "Use of sting agonist as cancer treatment", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:j8SEvjWlNXcC", "citedby": "0"}, {"bib": {"title": "Tumor and host genomics regulating immunotherapy efficacy", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:0CzhzZyukY4C", "citedby": "0"}, {"bib": {"title": "Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts", "year": "2018"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:jSAVyFp_754C", "citedby": "0"}, {"bib": {"title": "A dual and opposing role for tumor intrinsic type-II interferon sensing in tumor establishment and acquired resistance", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:CNPyR2KL9-0C", "citedby": "0"}, {"bib": {"title": "Tumor cell-intrinsic STING signaling and regulation of IFN-beta gene expression", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kVjdVfd2voEC", "citedby": "0"}, {"bib": {"title": "Pseudoprogression manifesting as recurrent ascities with anti-PD-1 therapy", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WqliGbK-hY8C", "citedby": "0"}, {"bib": {"title": "Fabrication of fillable microparticles and other complex 3D microstructures", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:e5wmG9Sq2KIC", "citedby": "0"}, {"bib": {"title": "2017 William B. Coley Award", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hqOjcs7Dif8C", "citedby": "0"}, {"bib": {"title": "Genomic analysis of bladder cancer immunophenotypes", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HbR8gkJAVGIC", "citedby": "0"}, {"bib": {"title": "Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:S16KYo8Pm5AC", "citedby": "0"}, {"bib": {"title": "1225PDPrognostic impact of early complete metabolic response on FDG-PET, in BRAF V600 mutant metastatic melanoma patients treated with combination vemurafenib & cobimetinib", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:vDZJ-YLwNdEC", "citedby": "0"}, {"bib": {"title": "Agonist antibodies targeting OX40 and GITR enhance the activity of the IDO1-selective inhibitor epacadostat in preclinical models", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-6RzNnnwWf8C", "citedby": "0"}, {"bib": {"title": "Abstract SY25-04: Tumor and host factors regulating immunotherapy responsiveness", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:1taIhTC69MYC", "citedby": "0"}, {"bib": {"title": "BATF3 DENDRITIC CELLS DRIVE ADOPTIVE EFFECTOR T-CELL TRAFFICKING", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:GtLg2Ama23sC", "citedby": "0"}, {"bib": {"title": "Early-Onset Diabetes Mellitus, Immunodeficiency, and Cardiomyopathy Associated with Compound Heterozygous IKZF2 Mutations", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:pQTOvowfQioC", "citedby": "0"}, {"bib": {"title": "CHARACTERIZATION OF NON-T CELL-INFLAMED BLADDER CANCER TO ENHANCE IMMUNOTHERAPY RESPONSE", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:VaXvl8Fpj5cC", "citedby": "0"}, {"bib": {"title": "New developments in checkpoint-inhibition MAb immunotherapy", "year": "2017"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:jtI9f0ekYq0C", "citedby": "0"}, {"bib": {"title": "Abstract A104: T cell-mediated immune surveillance is inhibited by tumor-intrinsic signaling", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:evX43VCCuoAC", "citedby": "0"}, {"bib": {"title": "Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:2v_ZtQDX9iAC", "citedby": "0"}, {"bib": {"title": "Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:k_IJM867U9cC", "citedby": "0"}, {"bib": {"title": "Validation of activated molecular pathways in non-T cell-inflamed urothelial bladder cancer (UBC).", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WA5NYHcadZ8C", "citedby": "0"}, {"bib": {"title": "Abstract IA02: Immunotherapies based on restoring T cell function in tumor metastases", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:NyGDZy8z5eUC", "citedby": "0"}, {"bib": {"title": "Hier een korte vrije vertaling van een gedeelte uit het originele abstract, zie verder onderaan de foto en dit artikel", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SxCCDk4iOpsC", "citedby": "0"}, {"bib": {"title": "Abstract A173: Inhibition of the STING pathway by the AIM2 inflammasome", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:KaMxkj08jr0C", "citedby": "0"}, {"bib": {"title": "Walka zarazk\u00f3w", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:p2g8aNsByqUC", "citedby": "0"}, {"bib": {"title": "Abstract B154: Immune surveillance is thwarted by tumor-cell intrinsic \u03b2-catenin signaling", "year": "2016"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-f6ydRqryjwC", "citedby": "0"}, {"bib": {"title": "Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or-PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:U_HPUtbDl20C", "citedby": "0"}, {"bib": {"title": "Immune surveillance is thwarted by tumor-cell intrinsic beta-catenin signaling", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:1yQoGdGgb4wC", "citedby": "0"}, {"bib": {"title": "Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:f2IySw72cVMC", "citedby": "0"}, {"bib": {"title": "Abstract IA10: Effective immunotherapy regimens incorporating highly active human STING-activating cyclic dinucleotide derivatives", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:oi2SiIJ9l4AC", "citedby": "0"}, {"bib": {"title": "Abstract IA09: Molecular mechanisms controlling the T cell-inflamed tumor microenvironment: Implications for therapy", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:U4n9YNQMCAIC", "citedby": "0"}, {"bib": {"title": "Effective immunotherapy regimens incorporating highly active human STING-activating cyclic dinucleotide derivatives", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:pqnbT2bcN3wC", "citedby": "0"}, {"bib": {"title": "Abstract IA22: The immunobiology of the melanoma tumor microenvironment and efficacy of immunotherapies", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:roLk4NBRz8UC", "citedby": "0"}, {"bib": {"title": "Effect of denileukin diftitox (DD) on vaccine-induced T-cell responses and depletion of Tregs in melanoma.", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WC9gN4BGCRcC", "citedby": "0"}, {"bib": {"title": "Exploratory analysis of clinical and translational factors associated with the inflamed phenotype in HNSCC.", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:tKAzc9rXhukC", "citedby": "0"}, {"bib": {"title": "Inhibition of the STING pathway by the AIM2 inflammasome (INM2P. 352)", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:tH6gc1N1XXoC", "citedby": "0"}, {"bib": {"title": "The STING pathway and the T cell-inflamed tumor microenvironment R", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:qe6vwMD2xtsC", "citedby": "0"}, {"bib": {"title": "Erratum to STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors.[Immunity (2014), 41, 830-842, November 20].", "year": "2015"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:b1wdh0AR-JQC", "citedby": "0"}, {"bib": {"title": "Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:j7_hQOaDUrUC", "citedby": "0"}, {"bib": {"title": "Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote \u2026", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:DUooU5lO8OsC", "citedby": "0"}, {"bib": {"title": "Methods and compositions related to t-cell activity", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:isU91gLudPYC", "citedby": "0"}, {"bib": {"title": "1112P PHASE II STUDY OF NILOTINIB IN MELANOMA HARBORING KIT ALTERATIONS FOLLOWING PROGRESSION OR INTOLERANCE TO PRIOR KIT INHIBITION", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WF5omc3nYNoC", "citedby": "0"}, {"bib": {"title": "S2. Therapeutic strategies based on overcoming immune resistance mechanisms within the melanoma tumour microenvironment", "year": "2014"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:2VqYfGB8ITEC", "citedby": "0"}, {"bib": {"title": "Innate immune sensing of a growing tumor in vivo occurs via the host sting pathway and involves mitochondrial DNA transfer from cancer cells to DCs", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Ak0FvsSvgGUC", "citedby": "0"}, {"bib": {"title": "Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:R3hNpaxXUhUC", "citedby": "0"}, {"bib": {"title": "Gajewski et al.", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:YB4bud6kWLwC", "citedby": "0"}, {"bib": {"title": "Immunological Response to Cancer", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:BJrgspguQaEC", "citedby": "0"}, {"bib": {"title": "Forcing NF-\u03baB in T cells promotes tumor rejection (P2042)", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:MhiOAD_qIWkC", "citedby": "0"}, {"bib": {"title": "Forcing NF-B in T cells promotes tumor rejection", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:F9fV5C73w3QC", "citedby": "0"}, {"bib": {"title": "Abstract SY26-03: Innate immune sensing of tumors via the host STING pathway as a bridge to a spontaneous adaptive T cell response.", "year": "2013"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SnGPuo6Feq8C", "citedby": "0"}, {"bib": {"title": "Synergistic Therapeutic Effect of Blocking Two Immune Inhibitory Pathways Concurrently in the Context of a Tolerogenic Tumor Microenvironment in vivo", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SGW5VrABaM0C", "citedby": "0"}, {"bib": {"title": "Autophagy in Tumor Cells is Critical for Innate Immune Sensing of a Growing Tumor and Bridging to an Adaptive Immune Response", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:tzM49s52ZIMC", "citedby": "0"}, {"bib": {"title": "Forcing NF-kappa B in T Cells Promotes Tumor Rejection", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:olpn-zPbct0C", "citedby": "0"}, {"bib": {"title": "The AIM2 Inflammasome Inhibits IFN-beta Production Triggered by Tumor-derived DNA", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:1qzjygNMrQYC", "citedby": "0"}, {"bib": {"title": "NO-95. DEVELOPMENT OF ANTIBODIES TO THE VOLTAGE-GATED POTASSIUM CHANNEL FOLLOWING IMMUNOMODULATORY THERAPY IN A CASE OF ATAXIA ASSOCIATED WITH MELANOMA", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hsZV8lGYWTMC", "citedby": "0"}, {"bib": {"title": "Phase II study of the anti-ganglioside GD3 mouse/human chimeric antibody KW2871 combined with high dose interferon-a2b in patients with metastatic melanoma.", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Aul-kAQHnToC", "citedby": "0"}, {"bib": {"title": "Predictive Biomarkers as a Guide to Future Therapy Selection in Melanoma", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-jrNzM816MMC", "citedby": "0"}, {"bib": {"title": "Targeted therapeutics in melanoma", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:tuHXwOkdijsC", "citedby": "0"}, {"bib": {"title": "249 Innate and adaptive immunity regulated within the tumor microenvironment", "year": "2012"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:9Nmd_mFXekcC", "citedby": "0"}, {"bib": {"title": "Metabolic response by FDG-PET correlates with exon11 KIT mutation in patients with mucosal or acral melanoma or melanoma arising on chronically sun damaged skin treated with \u2026", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:RYcK_YlVTxYC", "citedby": "0"}, {"bib": {"title": "Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:yxmsSjX2EkcC", "citedby": "0"}, {"bib": {"title": "Abstract SY19-01: Identifying and overcoming immune barriers at the level of the tumor microenvironment", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:XUvXOeBm_78C", "citedby": "0"}, {"bib": {"title": "OFFICE ONCOLOGY", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:PVgj2kMGcgYC", "citedby": "0"}, {"bib": {"title": "Forced NF-\u03baB in T cells leads to tumor rejection (48.24)", "year": "2011"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:nb7KW1ujOQ8C", "citedby": "0"}, {"bib": {"title": "A Single Dose of Ontak Administration is Not Sufficient to Deplete Tregs in Stage IV Melanoma Patients", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:jL-93Qbq4QoC", "citedby": "0"}, {"bib": {"title": "Interferon-beta Secretion in the Tumor Microenvironment can Cause Potent Tumor Control Through Host Cells Independently from Adaptive Immunity", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Dip1O2bNi0gC", "citedby": "0"}, {"bib": {"title": "Trafficking of Positive and Negative Regulatory Immune Cells into the Tumor Microenvironment", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ILKRHgRFtOwC", "citedby": "0"}, {"bib": {"title": "A State of Dominant Tolerance is Rapidly Induced with Intravenous Dissemination but not with Subcutaneous Implantation in a Murine Leukemia Model", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:bEWYMUwI8FkC", "citedby": "0"}, {"bib": {"title": "Taylor, W. Chris; Muss, Hyman B.", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LO7wyVUgiFcC", "citedby": "0"}, {"bib": {"title": "\u03b2-catenin inhibits T cell activation by selective interference with LAT-PLC-\u03b31 phosphorylation.(50.12)", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:27LrP4qxOz0C", "citedby": "0"}, {"bib": {"title": "Designer Ligands Specific for Kv1. 3 Channels from a Scorpion Neurotoxin-Based Library", "year": "2010"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:w1MjKQ0l0TYC", "citedby": "0"}, {"bib": {"title": "Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T-cell Depletion and Homeostatic Proliferation", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:AXkvAH5U_nMC", "citedby": "0"}, {"bib": {"title": "Abstract# SY11-4: Immune regulation from within the solid tumor microenvironment", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:KNjnJ3z-R6IC", "citedby": "0"}, {"bib": {"title": "In vitro PTEN deletion in peripheral T cells enhances activation but does not replace CD28 costimulation or prevent anergy (35.37)", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:M05iB0D1s5AC", "citedby": "0"}, {"bib": {"title": "Protein Kinase C Focusing at the cSMAC Is a Consequence rather than Cause of TCR Signaling and Is Dependent on the MEK/ERK Pathway", "year": "2009"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:5ugPr518TE4C", "citedby": "0"}, {"bib": {"title": "Evidence for Selection of a Resistant Tumor Microenvironment Following Successful Clinical Response to a Multi-peptide+ IL-12 Melanoma Vaccine", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:prdVHNxh-e8C", "citedby": "0"}, {"bib": {"title": "Blockade of PD-1/PD-L1 Interactions is Paradoxically Detrimental in a T Cell Adoptive Transfer Tumor Therapy Model", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:GFxP56DSvIMC", "citedby": "0"}, {"bib": {"title": "PL-24 Immunotherapy for melanoma: overcoming mechanisms of resistance in the tumor microenvironment", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:C33y2ycGS3YC", "citedby": "0"}, {"bib": {"title": "Immune Suppression in Solid Tumors", "year": "2008"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:L_l9e5I586QC", "citedby": "0"}, {"bib": {"title": "Failure at the Effector Phase: Immune Resistance in the Tumor Microenvironment", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:NaGl4SEjCO4C", "citedby": "0"}, {"bib": {"title": "Phase II study of oxaliplatin, docetaxel, and sargramostim (GM-CSF) in patients with previously treated advanced melanoma", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:yD5IFk8b50cC", "citedby": "0"}, {"bib": {"title": "Regulation of CD28 costimulation versus anergy in T cells by RasGRP and DGK-\u03b1 (88.27)", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:pAkWuXOU-OoC", "citedby": "0"}, {"bib": {"title": "Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections.", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:QUX0mv85b1cC", "citedby": "0"}, {"bib": {"title": "Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor-Immune Escape", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:9c2xU6iGI7YC", "citedby": "0"}, {"bib": {"title": "John Fabre Nasser Farschtschi Joseph Fay Todd Fehniger Carmen Fernandez", "year": "2007"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:g3aElNc5_aQC", "citedby": "0"}, {"bib": {"title": "T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha (vol 7, pg 1166, 2006)", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:AZju0d2GQJ0C", "citedby": "0"}, {"bib": {"title": "The Melanoma Tumor Microenvironment and Resistance to T Cell-Based Immunotherapy", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:LdasjJ6CEcoC", "citedby": "0"}, {"bib": {"title": "Adoptive Transfer of CD25-Depleted Polyclonal T Cells Into Lymphopenic Hosts Promotes Spontaneous Tumor Rejection", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:YOwf2qJgpHMC", "citedby": "0"}, {"bib": {"title": "A phase I study of G3139 in combination with RICE chemotherapy in relapsed non-Hodgkin\u2019s lymphoma (NHL)", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:AvfA0Oy_GE0C", "citedby": "0"}, {"bib": {"title": "Phage display antibodies to allelic determinants of canine blood cells H.-W. Chang, DD Nguyen, E. Washington, ID Walker and SA Holloway (Australia) 1 Dynamic quantification of \u2026", "year": "2006"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:sNmaIFBj_lkC", "citedby": "0"}, {"bib": {"title": "cSMAC formation is not required for granule-mediated cytolytic activity in CD8+ effector T cells", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:OP4eGU-M3BUC", "citedby": "0"}, {"bib": {"title": "Forced maintenance of Ras signaling in naive CD4 (+) T cells blocks Th1/Th2 forward differentiation", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:edDO8Oi4QzsC", "citedby": "0"}, {"bib": {"title": "Glucose but not oxygen is required to support expression of critical effector genes in CD8+ T cells", "year": "2005"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:u5HHmVD_uO8C", "citedby": "0"}, {"bib": {"title": "Melanoma Gene Expression Profiles To Identify Mechanisms of Tumor Resistance to a Multi-Peptide/IL-12 Vaccine", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:CHSYGLWDkRkC", "citedby": "0"}, {"bib": {"title": "The University of Chicago experience with a reduced intensity allogeneic peripheral blood stem cell transplant preparative regimen using fludarabine, cyclophosphamide, and \u2026", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:2l5NCbZemmgC", "citedby": "0"}, {"bib": {"title": "Phase II trial of O6-benzylguanine (O6BG) and BCNU in patients with advanced melanoma", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:2KloaMYe4IUC", "citedby": "0"}, {"bib": {"title": "in the Immune Response", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:uJ-U7cs_P_0C", "citedby": "0"}, {"bib": {"title": "Gene expression profiles of stromal cells in the melanoma tumor microenvironment: In search of patterns that predict response to immune effector function", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:YsrPvlHIBpEC", "citedby": "0"}, {"bib": {"title": "Immune response in malignant ascites from a melanoma patient treated with anti-CTLA-4 mAb", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SjuI4pbJlxcC", "citedby": "0"}, {"bib": {"title": "Homeostasis-driven proliferation in the lymphopenic setting enhances CD8+ T cell-mediated anti-tumor responses through mechanisms which modulate activation state of effectors \u2026", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:z_wVstp3MssC", "citedby": "0"}, {"bib": {"title": "Long-term follow up after non-myeloablative allogeneic stem cell transplantation for renal cell carcinoma: the university of Chicago experience", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:iH-uZ7U-co4C", "citedby": "0"}, {"bib": {"title": "Original Reports-PHASE I AND CLINICAL PHARMACOLOGY-Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic Malignancies", "year": "2004"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:1yWc8FF-_SYC", "citedby": "0"}, {"bib": {"title": "PD-L1 on murine and human tumors and its possible role in immune evasion: P997", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:F2UWTTQJPOcC", "citedby": "0"}, {"bib": {"title": "Farnesyltransferase inhibitors suppress T cell activation by post-transcriptional regulation of cytokine production: P1031", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ZzlSgRqYykMC", "citedby": "0"}, {"bib": {"title": "Glucose regulates p70S6K activation and IFN-gamma production by CD8 (+) effector T cells", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SAZ1SQo2q1kC", "citedby": "0"}, {"bib": {"title": "ORIGINAL REPORTS-Melanoma-Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell \u2026", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:eO3_k5sD8BwC", "citedby": "0"}, {"bib": {"title": "MOLECULAR BASIS OF CELL AND DEVELOPMENTAL BIOLOGY-Gene Array and Protein Expression Profiles Suggest Post-transcriptional Regulation during CD8+ T Cell Differentiation.", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:fbc8zXXH2BUC", "citedby": "0"}, {"bib": {"title": "CELLULAR IMMUNOLOGY AND IMMUNE REGULATION-Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:umqufdRvDiIC", "citedby": "0"}, {"bib": {"title": "Cutaneous Melanoma", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:ZfRJV9d4-WMC", "citedby": "0"}, {"bib": {"title": "Principles of Cancer Immunotherapy", "year": "2003"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:JoZmwDi-zQgC", "citedby": "0"}, {"bib": {"title": "Cutting Edge: Targeted Ligation of CTLA-4 In", "year": "2002"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:-95Q15plzcUC", "citedby": "0"}, {"bib": {"title": "ORIGINAL REPORTS-Genitourinary Cancer-Allogeneic Stem-Cell Transplantation of Renal Cell Cancer After Nonmyeloablative Chemotherapy: Feasibility, Engraftment, and Clinical Results", "year": "2002"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SeFeTyx0c_EC", "citedby": "0"}, {"bib": {"title": "T Lymphocyte Responses: Development", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:owLR8QvbtFgC", "citedby": "0"}, {"bib": {"title": "Direct antigen presentation can induce CD8 (+) T cell-dependent tumor rejection: Host MHC class I molecules are required for the survival, but not activation, of a tumor \u2026", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:dBIO0h50nwkC", "citedby": "0"}, {"bib": {"title": "CD28 co-ligation is not required for JNK activation in T cells", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kz9GbA2Ns4gC", "citedby": "0"}, {"bib": {"title": "Coordinate upregulation of the actin cytoskeleton program during T cell differentiation", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:zYLM7Y9cAGgC", "citedby": "0"}, {"bib": {"title": "CELLULAR IMMUNOLOGY AND IMMUNE REGULATION-Absence of CTLA-4 Lowers the Activation Threshold of Primed CD8+ TCR-Transgenic T Cells: Lack of Correlation with Src Homology Domain \u2026", "year": "2001"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:bnK-pcrLprsC", "citedby": "0"}, {"bib": {"title": "Circulating CD11C (+)/CD83 (+) mature dendritic cells in vivo following sequential Flt-3 ligand and interleukin-2 administration in renal carcinoma patients.", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:1DsIQWDZLl8C", "citedby": "0"}, {"bib": {"title": "IL-12 production by immature but not mature monocyte-derived human dendritic cells.", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:48xauSegjOkC", "citedby": "0"}, {"bib": {"title": "Introduction of H-Ras into normal T-cells using a novel adenovirus transduction system reveals selective promotion of Th1 differentiation and IL-2 production.", "year": "2000"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:M7yex6snE4oC", "citedby": "0"}, {"bib": {"title": "Development of an assay to detect farnesyl protein transferase inhibitor-Mediated Ras retargeting in leukemic cells.", "year": "1999"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Ri6SYOTghG4C", "citedby": "0"}, {"bib": {"title": "Clinical case", "year": "1999"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:qmtmRrLr0tkC", "citedby": "0"}, {"bib": {"title": "159 The regulation of FAS and FASL by ionizing radiation", "year": "1999"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:EPG8bYD4jVwC", "citedby": "0"}, {"bib": {"title": "Pathogenesis and immune", "year": "1999"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:_kc_bZDykSQC", "citedby": "0"}, {"bib": {"title": "Ex-vivo expansion of dendritic cells derived from peripheral CD34 (+) cells: Optimization for clinical application.", "year": "1998"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:Tiz5es2fbqcC", "citedby": "0"}, {"bib": {"title": "p68 Pak activity in naive T lymphocytes is promoted by CD28 costimulation and Th1 differentiation.", "year": "1998"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kJDgFkosVoMC", "citedby": "0"}, {"bib": {"title": "Coadministration of IL-12 obviates the need to use dendritic cells in tumor antigen peptide-pulsed antigen-presenting cell (APC) vaccination.", "year": "1998"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:fQNAKQ3IYiAC", "citedby": "0"}, {"bib": {"title": "Second Signals for Lymphocyte Activation", "year": "1998"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:yMeIxYmEMEAC", "citedby": "0"}, {"bib": {"title": "Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof", "year": "1997"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:hMod-77fHWUC", "citedby": "0"}, {"bib": {"title": "Tumor antigen peptide-specific immunization: Preclinical data and development of a rational protocol for treatment of melanoma.", "year": "1996"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4OULZ7Gr8RgC", "citedby": "0"}, {"bib": {"title": "P815 tumor-bearing mice are not systemically tolerant, and can be successfully treated by immunization with irradiated IL-12-but not B7-1-transfected tumor or cells", "year": "1996"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:eMMeJKvmdy0C", "citedby": "0"}, {"bib": {"title": "A SELECTIVE SIGNALING DEFECT IN THE FUNCTIONAL ACTIVATION OF ANTIGEN-SPECIFIC T-LYMPHOCYTE CLONES IN THE ABSENCE OF PROTEIN-TYROSINE KINASE P59 (FYN)", "year": "1994"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:VLnqNzywnoUC", "citedby": "0"}, {"bib": {"title": "GENERATION AND FUNCTIONAL ACTIVATION OF ANTIGEN-SPECIFIC T (H) 1 AND T (H) 2 CLONES IN THE ABSENCE OF PROTEIN-TYROSINE KINASE P59 (FYN)", "year": "1994"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:9vf0nzSNQJEC", "citedby": "0"}, {"bib": {"title": "INTERLEUKIN-2 (IL-2) SIGNAL-TRANSDUCTION IN THE ABSENCE OF PROTEIN-TYROSINE KINASE P59 (FYN)", "year": "1994"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:4TOpqqG69KYC", "citedby": "0"}, {"bib": {"title": "BRAIN MICROVESSEL ENDOTHELIAL OR SMOOTH-MUSCLE CELLS SELECTIVELY ACTIVATE OR ANERGIZE TH1 VS TH2 CLONES", "year": "1992"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WbkHhVStYXYC", "citedby": "0"}, {"bib": {"title": "Differential Regulation of Murine T Lymphocyte Subsets", "year": "1992"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:k8Z6L05lTy4C", "citedby": "0"}, {"bib": {"title": "DIFFERENTIAL EXPRESSION OF PHOSPHOLIPASE C-GAMMA-1 AND C-GAMMA-2 IN LYMPHOCYTE POPULATIONS AND CELL-LINES", "year": "1991"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:YsMSGLbcyi4C", "citedby": "0"}, {"bib": {"title": "35TH FORUM IN IMMUNOLOGY-DISCUSSION", "year": "1991"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:PVjk1bu6vJQC", "citedby": "0"}, {"bib": {"title": "Brain microvessel smooth muscle (SM) and endothelium (En) each preferentially present antigen to a different CD4+ T-cell subset", "year": "1991"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:SIv7DqKytYAC", "citedby": "0"}, {"bib": {"title": "STIMULATION OF TH2 HELPER T LYMPHOCYTE CLONES BY HEPATIC ANTIGEN PRESENTING CELLS OF MRL/LPR MICE", "year": "1991"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:FPJr55Dyh1AC", "citedby": "0"}, {"bib": {"title": "CD4+ T-cell subsets: Regulation of differentiation and function: Discussion", "year": "1991"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:kzcrU_BdoSEC", "citedby": "0"}, {"bib": {"title": "STIMULATION OF TH2 HELPER LYMPHOCYTE-T CLONES BY HEPATIC ANTIGEN PRESENTING CELLS (APC) OF MRL MICE", "year": "1990"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:fFSKOagxvKUC", "citedby": "0"}, {"bib": {"title": "Lymphokines and differential regulation of T lymphocyte responses", "year": "1990"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:bKqednn6t2AC", "citedby": "0"}, {"bib": {"title": "\" Anergy\" of TO Helper T Lymphocytes Induces Downregulation of TI Characteristics and a Transition to a Ta2-1ike Phenotype"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:WJVC3Jt7v1AC", "citedby": "0"}, {"bib": {"title": "A Phase 1 Dose Escalation and Cohort Expansion Study of Lirilumab (Anti-KIR; BMS-986015) Administered in Combination With Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in \u2026"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:geHnlv5EZngC", "citedby": "0"}, {"bib": {"title": "41 Caspases and immunity in a deadly grip 50 Invariant natural killer T cells as sensors and managers of inflammation 59 The dynamic lives of T cells: new approaches and themes"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:u9iWguZQMMsC", "citedby": "0"}, {"bib": {"title": "Vemurafenib and Cobimetinib Potently Inhibit pS6 Signaling in V600 Mutation\u2013Positive Locally Advanced or Metastatic Melanoma From BRIM7 Study"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:HDshCWvjkbEC", "citedby": "0"}, {"bib": {"title": "Mutation\u2013Positive Locally Advanced or Metastatic Melanoma From BRIM7 Study"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:IWHjjKOFINEC", "citedby": "0"}, {"bib": {"title": "Immunity and Cancer"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:KlAtU1dfN6UC", "citedby": "0"}, {"bib": {"title": "Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through"}, "source": "citations", "id_citations": "VqskH6cAAAAJ:MXK_kJrjxJIC", "citedby": "0"}]}